Carregant...
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis
Ruxolitinib (INCB018424) is the first potent, selective, oral inhibitor of JAK1 and 2 being developed for clinical use. Its major cellular and systemic effects are proliferation inhibition, apoptosis induction and reduction in cytokine plasma levels, all mediated by the drug's inhibition of JAK...
Guardat en:
| Publicat a: | Future Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5147419/ https://ncbi.nlm.nih.gov/pubmed/21919691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.11.81 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|